8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2010

NxSTAGE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-51567	04-3454702
(State or other jurisdiction of Incorporation	(Commission File Number)	(IRS Employer Identification No.)

439 South Union Street, 5th Floor, Lawrence, MA	01843
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (978) 687-4700

(Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 15, 2010, NxStage Medical, Inc. (the “Company”) appointed Joseph E. Turk, Jr. as the Company’s President, North America. Mr. Turk will continue to manage the Company’s North American commercial teams across the Company’s three markets (Home, Critical Care, and In-Center) and will be responsible for driving NxStage’s worldwide product portfolio. He will continue to report to the Jeffrey H. Burbank, the Company’s Chief Executive Officer. Mr. Turk, age 43, had been the Company’s Senior Vice President, Commercial Operations since 2006 and prior to that was our Vice President, Sales and Marketing since May 2000. In connection with this appointment, Mr. Turk’s base compensation was increased from $268,000 to $285,000.

Item 7.01 Regulation FD Disclosure.

A copy of the Company’s press release announcing his appointment dated December 20, 2010 is attached hereto as Exhibit 99.1 and is incorporated in this report by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number	Description
99.1	Press Release dated December 20, 2010

2

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		NXSTAGE MEDICAL, INC.
Date: December 20, 2010	By:	/s/ Jeffrey Burbank
		Jeffrey Burbank
		Chief Executive Officer

3

EXHIBIT INDEX

Exhibit
Number	Description
99.1	Press Release dated December 20, 2010

4

EX-99.1

EXHIBIT 99.1

NxStage Names Joseph Turk President, North America

LAWRENCE, MA, December 20, 2010—NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, today announced that Joseph E. Turk, Jr., has been promoted to the position of President of its North American operations. Reporting to Jeffrey Burbank, Chief Executive Officer of NxStage, Mr. Turk will continue to manage the Company’s North American commercial teams across the Company’s three markets (Home, Critical Care, and In-Center) and will be responsible for driving NxStage’s worldwide product portfolio.

“Joe has been a driving force behind the Company’s ability to successfully execute against its strategic initiatives and achieve its goals,” said Jeffrey Burbank, Chief Executive Officer of NxStage. “As the scale of our business increases, Joe’s exceptional track record as a multi-faceted operating executive will be a great asset to our growth initiatives across all three of our markets.”

Mr. Turk, age 43, joined NxStage Medical in 2000 as Vice President of Marketing. He served as Vice President of Sales and Marketing from 2002 to 2006, and most recently served as Senior Vice President of Commercial Operations since 2006.

“NxStage is a great company with a tremendous future and growth opportunities across all its markets, and I feel privileged to have worked with such a talented team in achieving our milestones to date,” said Mr. Turk. “I am proud of this recognition and I look forward to continuing to deliver value to our patients, customers, partners, and all of our stakeholders.”

Before joining NxStage, Mr. Turk served as Director of New Business Development at Boston Scientific. Prior to this, he was one of the leaders of McKinsey & Company’s Midwest Health Care and Biotechnology Practice as a Senior Engagement Manager in the firm’s Chicago Office.

Mr.Turk received his AB in Economics from Wabash College and an MBA in Marketing, Finance and Operations from Northwestern University’s J.L. Kellogg School.

About NxStage Medical, Inc.

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage’s website at www.nxstage.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors that are discussed in NxStage’s Quarterly Report on Form 10-Q for the period ended September 30, 2010 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

# # #